At its meeting today the Financial Supervision Commission approved Bioiasis Jsc's prospectus for a secondary public offering of shares.

The issue's value stands at 200,000 leva allocated in as many common shares with a face value of 1 lev representing the company's capital.

Bioiasis's Board of Directors includes Georgios Kisas (chair and executive director), Dimitrios Sotiropulos, and Dimitrios Dumbalis. Main shareholders are Georgios Kisas (70%) and Dimitrios Sotiropoulos (30%).

The company's core activity is purchase and resale of goods, commercial representation and intermediation, export and import, wholesale of medical products, disinfectants, hygiene products, cosmetics etc.

The company is a distributor of products in the filed of neurosurgery, invasive cardiology, orthopaedy, rheumatology, intensive care.

Bioiasis Jsc sell its products directly to hospitals, pharmacies and consumers and participates in medical tenders.